Home
overview

SMi's Superbugs & Superdrugs Conference is now in it's 13th year.

Visit the 2011 event page

 


 
2010 Past Event Details:

 

Since their discovery antimicrobial drugs have dramatically reduced the danger of infectious diseases. However the emergence of resistant strains of microbes has now greatly reduced the effectiveness of these drugs. Resistant strains are responsible for regular headline news, from E.Coli outbreaks to the H1N1 pandemic and cost global health services ever increasing amounts of money.

The recent ECDC/EMEA Technical Report - The bacterial challenge: time to react has highlighted the urgent need for development of new antimicrobial drugs.

"Industry's pipeline contains very few new antibiotics active against multidrug-resistant bacteria. Without stimulating research and development into new antibiotics, an increasing number of infected patients will be without effective treatment". Bo Aronsson, EMEA.

"A future without effective antibiotics will exacerbate a situation where already at least 25,000 patients in the EU each year die from infections due to multidrug-resistant bacteria. Patients suffering from healthcare-associated infections will be particularly hard hit" Dominique Monnet, ECDC

SMi's 12th Annual Conference will bring you up to date with new and emerging products in the antimicrobials market, with a particular focus on antibacterials and antifungals and allow you to learn from and network with some of the leading individuals and organisations in this ever important area.

 

 

 

Key topics include:

  • A global update on emerging antibiotic resistant pathogens 
  • Developments in the emerging global challenge of bacterial multi-drug resistance 
  • Tackling resistance in gram-negative bacteria 
  • Forming strategic alliances with large pharma to develop new antibacterials 
  • New approaches to fungal and protozoal infections  
  • Insights into novel therapies for overcoming resistance

 

 

 

Feedback from our previous events includes:

"Excellent range of topics from discovery to development and regulatory challenges." Senior Representative, NovaBay Pharmaceuticals

"This was well organised!" Senior Representative, ViroPharma Ltd

"Very well organised. Some excellent topics" Senior Representative, IPSAT Therapies

"Very informative" Senior Representative, Plant Bioscience

By attending this event you will be able to:

  • Meet the leading figures in antimicrobial development
  • Learn more about novel strategies and solutions for overcoming resistance
  • Increase your knowledge through informative and thought provoking presentations
  • Transfer knowledge with fellow senior executives
  • Engage with potential new clients and suppliers
 

 

All those responsible for research, medical microbiology, antimicrobial therapeutics, clinical development and business development, including:

 
  • Chief Scientific Officers
  • Senior Vice Presidents
  • Chief Medical Officers
  • Research Scientists
  • Clinical Microbiologists
  • R&D Project Managers

 

  • Heads of Anti-Infectives Discovery
  • Clinical Trials Managers
  • Principal Scientists
  • Senior Vice Presidents of R&D
  • Business Development Managers
  • Product Managers
 
 

 Organisations represented at our previous Superbugs and Superdrugs conference include:

 

  • Achaogen
  • Affinium Pharmaceuticals
  • Astellas Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Cubist Pharmaceuticals
  • Destiny Pharma
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck Sharp & Dohme
  • NeuTec Pharma
  • Novartis
  • Novexel
  • Novo Nordisk
  • Rib-X
  • Tibotec 
 

 

Conference programme

8:30 Registration and coffee

9:00 Chairman's opening remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 The role of pharma SMEs in meeting the challenge for new antimicrobials

Bill Love

Bill Love, Chief Executive Officer, Destiny Pharma

  • SME/biotechs - filling the big pharma gap
  • Gaining support and finance for new antimicrobial product development
  • 9:45 Government support for the development of new antimicrobials

    Jennifer Hannesschlager

    Jennifer Hannesschlager, Principal, Tiber Creek Partners

  • Funding opportunities
  • Supporting R&D
  • Approaches for support of novel biotechnologies
  • Leveraging data from more centralised health care systems to develop policy and regulation
  • 10:25 Morning Coffee

    10:45 Infectious disease biomarkers

    Ajit Lalvani

    Ajit Lalvani, Chair in Infectious Diseases, National Heart and Lung Institute, Imperial College

  • Biomarkers in TB
  • T-cells
  • Usage
  • Next steps
  • 11:20 Update on emerging pathogens

    Peter Hawkey

    Peter Hawkey, Professor of Public Health Bacteriology, University of Birmingham & Health Protection Agency

    11:55 Antibiotic peptides in dematology

    Jan Alenfall

    Jan Alenfall, CEO, DermaGen

  • Antimicrobial peptides, challenges and potential
  • Peptide screening
  • Target specificity and spectrum of activity
  • Drug development in a virtual company
  • DPK-060 an antimicrobial peptide in clinical development
  • 12:30 Networking Lunch

    13:45 Overcoming resistance

    Alan Johnson

    Alan Johnson, Clinical Scientist, Health Protection Agency

  • How can resistance be overcome
  • The importance of surveillance and feedback of data
  • Infection control
  • Antibiotic stewardship
     
  • 14:20 Multidrug resistance - Acinectobacter baumannii

    David Wareham

    David Wareham, Clinical Senior Lecturer & Honorary Consultant , Centre for Infectious Disease, Barts and The London School of Medicine and Dentistry

  • Multidrug resistance
  • Reduced susceptibility to tigecycline
  • Treatments
  • Threat to the critically ill
  • 14:55 Novel appraoches to prevent side effects and emergence of bacterial resistance during antibiotic treatment

    Jean de Gunzburg

    Jean de Gunzburg, CSO, Da Volterra

  • Emergence of resistance during antibiotic treatments: clinical data
  • Possible strategies of prevention
  • Products in development
  • Development challenges/opportunities
  • 15:30 Afternoon Tea

    15:55 Diarylquinolines and Tuberculosis treatment: TMC207 an Evolving Story?

    Anil Koul

    Anil Koul, Head, Department of Antimicrobial Research, Johnson & Johnson

  • TMC207 as an novel ATP synthase target inhibitor
  • Selectivity vis a vis Human ATP synthase
  • Progress update towards the clinics
     
  • 16:30 Responding to the emerging global challenge of bacterial multi-drug resistance

    John Mueller

    John Mueller, Senior Director, Biology Lead, Antibacterials Research Unit, Pfizer

  • Current state and future directions of pharmaceutical antibacterial research
  • Discovering new antibacterial agents in the 21st century
  • Alternative therapeutic and preventative approaches for serious nosocomial infections
  • 17:05 Chairman's closing remarks

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    8:30 Re-registration & coffee

    9:00 Chairman's opening remarks

    Anthony Coates

    Anthony Coates, Professor of Medical Microbiology, St George's, University of London

  • Non-multiplying bacteria
  • A new way to make antibiotics
  • A new anti-Gram positive topical antibiotic
  • 9:10 Tackling antibiotic resistance in gram-negative bacteria

    Laurenz Kellenberger

    Laurenz Kellenberger, Chief Scientific Officer, Basilea Pharmaceutica

  • Resistance mechanisms
  • Strategies to tackle antibiotic resistance
  • Possible solutions
  • Beta-lactams
  • 9:45 Novel small molecule and natural product semi-synthesis strategies for antibacterial agents

    Chester Metcalf III

    Chester Metcalf III, Vice President, Discovery Chemistry, Cubist Pharmaceuticals

  • Drug discovery strategies and approaches
  • Lipopeptide semi-synthesis
  • MIC and in vivo efficacy
  • Structure-based methods and X-ray co-crystal structure
  • 10:25 Morning Coffee

    10:45 Lantibiotics as leads for new antimicrobials

    Mike Dawson

    Mike Dawson, Chief Scientific Officer, Novacta Biosystems

  • Introduction to lantibiotics
  • Structural modification by molecular biology and chemistry
  • NVB302, a selective antibiotic for Clostridium difficile infection
  • Lantibiotics for systemic infection
  • 11:20 The path from biological activity to drug - LytixarTM (LTX-109)

    Anders Fugelli

    Anders Fugelli, Head of Business Development, Lytix Biopharma

  • Cationic antimicrobial peptides - a much-talked-about source of novel drugs
  • Building the next generation peptidomimetics
  • LTX-109, a novel broad spectrum antimicrobial agent
     
  • 11:55 Strategic alliances with large Pharma to develop new antibacterials

    Graham Dixon

    Graham Dixon, Senior Vice President Drug Discovery, Galapagos

  • The alliance model
  • Galapagos' alliance in anti-infectives
  • Natural products as a source of anti-infectives
  • Galapagos' natural product platform
  • Challenges with natural product-based anti-infective programmes
     
  • 12:30 Networking Lunch

    13:45 New approaches to fungal and protozoal infections

    Katsura Hata

    Katsura Hata, Senior Researcher , Eisai Product Creation Systems

  • Ravuconazole as antifungal and antiprotozoal
  • Discovery of new target for antifungal
  • Pre-clinical efficacy of new antifungal
  • 14:20 Developing new echinocandins

    John Northfield

    John Northfield, Medical Advisor, Astellas Pharma Europe

  • Targets
  • Spectrum of activity
  • Toxicity
  • Clinical efficacy
  • 14:55 Phage therapy for microbial resistance

    Nick Housby

    Nick Housby, Chief Operating Officer & Director, Novolytics

  • Toxicity
  • Safety and efficacy
  • Preventative benefits
  • Internal and topical application
  • 15:30 Afternoon Tea

    15:55 Discovering novel classes of antibacterial agents - challenges and early successes

    Brian Noonan

    Brian Noonan, Director of Bioscience, Infection Discovery, AstraZeneca

  • The need for novel classes
  • The ongoing evolution of bacterial target validation
  • Learnings from industry's approach to lead generation
  • Progression towards the clinic
  • 16:30 New antimicrobials from natural products: Opportunities and challenges

    Frank Koehn

    Frank Koehn, Research Fellow, Pfizer

  • Landscape - Past and present
  • Targets, libraries and screening strategies
  • Exploiting unique opportunities
  • Overcoming unique challenges
  • 17:05 Chairman's Closing Remarks

    +

    Workshops

    Global health as an investment opportunity
    Workshop

    Global health as an investment opportunity

    Crowne Plaza Hotel - St James
    16th March 2010
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.